Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252067 | 0.77 | CDK2 (0.34) | CYP1A2CDK2CDK1 | |
| SCHEMBL14780256 | 0.68 | CDK2 (0.53) | CYP1A2CDK2CCNB2CDK1CCNB1 | |
| SCHEMBL5744033 | 0.67 | CYP1A2 (0.44) | CYP1A2CDK2CCNB2CDK1CCNB1 | |
| SCHEMBL14780097 | 0.67 | CDK2 (0.52) | CYP1A2CDK2CCNB2CDK1CCNB1 | |
| SCHEMBL14779614 | 0.65 | CDK1 (0.52) | CYP1A2CDK2CCNB2CDK1CCNB1 | |
| SCHEMBL14779332 | 0.65 | CDK2 (0.50) | CYP1A2CDK2CCNB2CDK1CCNB1 | |
| SCHEMBL14780248 | 0.63 | CDK2 (0.48) | CYP1A2CDK2CCNB2CDK1CCNB1 | |
| SCHEMBL2027216 | 0.60 | CDK2 (0.63) | CYP1A2CDK2CCNB2CDK1CCNB1 | |
| SCHEMBL3254318 | 0.60 | ADORA2A (0.50) | ADORA2AADORA2BHIF1APAX8 | |
| SCHEMBL14780258 | 0.59 | CDK2 (0.61) | CYP1A2CDK2CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0601092-B2 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SYNGENTA PARTICIPATIONS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-5994629-A | Positive selection | NOVARTIS AG (CH) | 1999-11-30 | — | — | US | disclosed |
| EP-0601092-B1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | NOVARTIS AG (CH) | 1999-07-07 | — | — | EP | disclosed |
| EP-0896063-A2 | Method for the selection of genetically transformed cells and compounds for use in the method | Novartis AG (CH) | 1999-02-10 | — | — | EP | disclosed |
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | disclosed |